scholarly journals The Yield of Echocardiography in the Diagnosis of Infective Endocarditis in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5177-5177
Author(s):  
Ghazi S. Alotaibi ◽  
Irwindeep Sandhu ◽  
Joseph M. Brandwein ◽  
Lalit Saini
Keyword(s):  
Staphylococcus Aureus ◽  
Acute Myeloid Leukemia ◽  
Infective Endocarditis ◽  
Myeloid Leukemia ◽  
Blood Cultures ◽  
Gram Negative ◽  
Viridans Group Streptococci ◽  
And Staphylococcus Aureus ◽  
Echocardiographic Findings ◽  
Acute Myeloid

Abstract INTRODUCTION: The pathogenesis of infective endocarditis (IE) , a typical biofilm-associated infectious disease frequently caused by commensal or pathogenic bacteria, is mainly attributed to the formation of septic vegetations, which are fibrin-platelet complexes embedded with bacteria on heart valves detected by echocardiography. Patients with acute myeloid leukemia (AML) are prone to neutropenia, immunosuppression and central venous catheters leading to high rates of bacteremia. It has been postulated that despite high rates of bacteremia, patients with AML undergoing intensive chemotherapy are only rarely able to form vegetations due the frequent thrombocytopenia associated with such treatment (McCormick 2002). Here, we sought to determine the rate of echocardiographic detection of IE in patients with AML and chemotherapy induced thrombocytopenia . METHODS: To assess the yield of echocardiography, we conducted a retrospective, single center, analysis of patients with AML who underwent treatment using anthracycline or fludarabine induction and intermediate/high dose cytarabine based consolidation. At all time points, patients with febrile neutropenia were empirically treated with piperacillin/tazobactam ± aminoglycosides and underwent appropriate investigations including blood cultures. Cultures were drawn every 24 to 48 hours with fevers and daily, if positive, till culture clearance. Patients with positive blood cultures for organisms associated with IE underwent an echocardiogram as standard of care. RESULTS: From January 2010 to January 2018, 296 patients underwent curative intent chemotherapy for treatment of acute myeloid leukemia (AML) at the University of Alberta Hospital, Edmonton, Canada. The median age of all patients was 56.7 years (IQR: 44-64) and 40.2% were females. During the induction or consolidation chemotherapy , 53 echocardiogram were done to investigate 53 episodes of bacteremia in 50 patients (16.9%) who had organisms associated with IE (Table 1). Two echocardiograms were done to investigate possible culture negative IE based upon clinical suspicion. Transesophageal echocardiogram were utilized in 19 patients (36%) while transthoracic echocardiogram were done in 34 patients (64%). The median platelets count on the day of the echocardiogram was 23 x109/L (IQR: 14-38). Viridans Group Streptococci and Staphylococcus aureus were the most frequent isolates cultured in the blood in 36% and 16% of cases, respectively. The median duration of bacteremia was 1 day (IQR 1-2). Three (5.6%) patients had echocardiographic findings suggestive of IE based on a positive transesophageal study (n=2) or transthoracic study (n=1). Among these, two were secondary to Enterococcus bacteria and involved the mitral valve and the third was secondary to a non-HACEK gram-negative bacteria leading to tricuspid valve involvement . CONCLUSION: This study is the first to suggest that despite the high prevalence of Viridans Group Streptococci and Staphylococcusaureus in patients with AML undergoing chemotherapy, echocardiographic findings of IE in these patients are rare, with the notable exception of Enterococcal and Non-HACEK gram negative organisms. In contrast, in the general population, Viridans Group Streptococci and Staphylococcus aureus and bacteremia are associated with IE in 20% and 63% %, respectively (Westling 2009, Rasmussen 2011). The low incidence in our cohort may be attributed to impaired fibrin-platelet deposition in these patients with inability to mount a vegetation response, or the early initiation of broad spectrum antibiotics. Given these findings, the value of routine echocardiography should be questioned in patients with AML without other clinical features of IE. Disclosures Sandhu: Bioverativ: Honoraria; Celgene: Honoraria; Novartis: Honoraria; Janssen: Honoraria; Amgen: Honoraria. Brandwein:Pfizer: Consultancy; Celgene: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding; Novartis: Consultancy; Lundbeck: Consultancy.

scholarly journals A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: Can we predict the organism?

2017 ◽  
Vol 06 (03) ◽  
pp. 132-133
Author(s):  
Preetam Kalaskar ◽  
Asha Anand ◽  
Harsha Panchal ◽  
Apurva Patel ◽  
Sonia Parikh ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Culture ◽  
Myeloid Leukemia ◽  
Bloodstream Infections ◽  
Blood Cultures ◽  
Consolidation Therapy ◽  
Gram Positive ◽  
Gram Negative ◽  
Culture Positive ◽  
Acute Myeloid

Abstract Introduction: The treatment of acute myeloid leukemia (AML) consists of induction therapy with anthracyclines and cytarabine followed by two to four cycles of consolidation therapy with high-dose cytarabine after achieving remission. There have been very few studies comparing infections during induction and consolidation. We have analyzed blood cultures of patients with AML during episodes of fever occurring during induction and consolidation, for comparing the bloodstream infections in both the phases. Materials and Methods: Blood cultures of patients during febrile episodes were collected from central venous catheters and peripheral blood, both during induction and consolidation therapy of AML. Results: The study population included 52 AML patients. During induction, there were 52 episodes of fever and 25 (48%) blood cultures were positive, 15 of these blood cultures reported Gram-negative organisms, 9 reported Gram-positive organisms and 1 as yeast. During consolidation, 47 episodes of fever were recorded and blood cultures were positive in 12, of which 7 were Gram-negative, 5 were Gram-positive. Conclusion: The incidence of blood culture positive infections during therapy of AML at our center was higher. The predominant organism isolated was Gram-negative both during induction and consolidation. The incidence of blood culture positive infections had decreased by 50% during consolidation.

scholarly journals False-positive blood cultures in a patient with acute myeloid leukemia

1999 ◽  
Vol 5 (12) ◽  
pp. 769-770 ◽  
Author(s):  
Nico E.I. Meessen ◽  
Elisabeth C.M. van Pampus ◽  
Jan A. Jacobs
Keyword(s):  
Acute Myeloid Leukemia ◽  
False Positive ◽  
Myeloid Leukemia ◽  
Blood Cultures ◽  
Acute Myeloid

Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3042-3042 ◽  
Author(s):  
Joshua Lukenbill ◽  
Lisa Rybicki ◽  
Mikkael A. Sekeres ◽  
Megan DiGiorgio ◽  
Thomas Fraser ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Blood Stream ◽  
Central Line ◽  
Streptococcus Viridans ◽  
Blood Stream Infections ◽  
Gram Negative ◽  
Definition Of ◽  
Acute Myeloid

Abstract Abstract 3042 Central line-associated blood stream infection (CLABSI) surveillance is increasingly utilized as an objective measure of quality of care provided by individual hospitals. CLABSI is defined by the National Healthcare Safety Network (NHSN) as a primary bloodstream infection (BSI) in a patient with a central line within the 48-hour period before the development of the BSI (NHSN CLABSI). This traditional definition of CLABSI includes pathogens better described as hospital-acquired blood stream infections (HABSI), such as enteric gram-negative bacilli (GNB) and streptococcus viridans - pathogens inherently more common in patients undergoing hematopoietic cell transplantation (HCT) due to the resultant neutropenia and disruption of mucosal barriers, and unlikely to be line-related. To avoid this misclassification, we have developed a modified CLABSI definition (MCLABSI) which excludes HABSI (DiGiorgio, Infect Control Hosp Epidemiol. 33: 865–8, 2012). MCLABSI includes all of the pathogens under the NHSN definition of CLABSI except Viridans group streptococci species in patients with mucositis, and Enterococcus, Enterobacteriaceae, or Candida species in patients with neutropenia or graft-vs-host disease of the gut. We compared the incidence of CLABSI and its impact on survival using both definitions in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients undergoing SCT. AML and MDS patients undergoing HCT between August 2009 and December 2011 were identified from the Cleveland Clinic Unified Transplant Database, and NHSN CLABSI and MCLABSI rates were obtained from the infection control database. CLABSI incidence was estimated using Kaplan-Meier method, and risk factors for mortality were identified using stepwise Cox proportional hazards analyses. Of the 73 patients identified (median age 52, range 16–70), 48 were male, 44 had AML, and 29 MDS. Patients received a median of 2 prior chemotherapy regimens (range 0–6), 3 had prior radiation, and 6 had prior transplant. 54 underwent myeloablative and 19 reduced-intensity preparative regimens; stem cell source included bone marrow (BM, n=34), peripheral stem cells (PSC, n=24), and cord blood cells (CBC, n=15). The median CD34+ count was 2.42 × 106/kg and median time to neutrophil recovery (absolute neutrophil count > 500/μL) was 14 days (range 6–24) with BM/PSC and 28 days (range 19–77) with CBC. Most (88%) had mucositis, including 17 (28%) with grade 3 or 4. Twenty-three (31.5%) developed NHSN CLABSI, compared to 8 (11.0%) who developed MCLABSI following HCT, of whom 16 (69.6%) and 7 (87.5%) died, respectively. The majority (16/23) of NHSN CLABSI occurred within 14 days (median 9 days, range 2–211 days) of HCT (Figure), varying from a median of 5 days (range 2–12 days) for CBC and 78 days for BM/PSC (range 7–211 days, p<.001). Pathogens in NHSN CLABSI included 11 enteric Gram-negative bacilli, 7 Streptococcus viridans group, 6 enterococcus (3 vancomycin resistant), 5 Staphylococcus (3 methicillin resistant), 2 fungal species, 2 Gram-positive bacilli, 1 Pseudomonas, 1 other Streptococcus species, and 1 Stenotrophomonas. MCLABSI occurred a median of 12 days (range 5–176 days) from HCT (Figure), 7 days for CBC (range 5–12 days) compared to 77 days (range 13–176 days) for BM/PSC (p<.001). Pathogens isolated in MCLABSI included 5 Staphylococcal species (3 MRSE), 2 Streptococcus viridans group, 2 GPB, 1 VRE, and 1 Pseudomonas. 4 NHSN CLABSI and 2 MCLABSI were polymicrobial, and 4 patients had recurrent CLABSI (all of whom died, including 3 MCLABSI). When NHSN CLABSI was analyzed as a time-varying covariate in univariable analysis, it was associated with an increased risk of mortality (HR 3.72, 95% CI 1.88 – 7.36, p<.001), as was MCLABSI (HR 2.96, CI 1.27–6.89, p=.012). CLABSI remained a significant risk factor for mortality in multivariable analysis, by both the NHSN (HR 7.14, CI 3.31 – 15.31, p<.001) and MCLABSI (HR 6.44, CI 2.28–18.18, p<.001) definitions. CLABSI is a common complication in AML and MDS patients undergoing SCT, and is associated with decreased survival. CLABSI is identified less commonly with the exclusion of HABSI in the modified definition, which more precisely identifies patients with BSI related to their central lines. The distinction between these definitions is important to guide preventative infectious control measures, particularly given CLABSI's role as a quality measure influencing reimbursement. Disclosures: Hill: Teva Pharmaceuticals: Honoraria, Speakers Bureau.

scholarly journals 2683. Evaluation of the Negative Predictive Value (NPV) of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab Screening in Acute Myeloid Leukemia Patients

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S942-S943
Author(s):  
Bailee Binks ◽  
Dayna McManus ◽  
Sarah Perreault ◽  
Jeffrey E Topal
Keyword(s):  
Staphylococcus Aureus ◽  
Acute Myeloid Leukemia ◽  
Antibiotic Therapy ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Nasal Swab ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Nasal Swabs ◽  
Mrsa Infection ◽  
Acute Myeloid

Abstract Background Methicillin-Resistant Staphylococcus aureus (MRSA) nasal swabs are utilized to guide discontinuation of empiric MRSA therapy. In multiple studies, MRSA nasal swabs has been shown to have a negative predictive value (NPV) of ~99% in non-oncology patients with pneumonia and other infections. At Yale New Haven Hospital (YNHH), a negative MRSA nasal swab is utilized in acute myeloid leukemia (AML) patients to de-escalate empiric MRSA antibiotic therapy. The primary endpoint was to assess the percentage of patients with a negative MRSA nasal swab who developed a culture documented (CD) MRSA infection during their admission. Secondary endpoints included the number of MRSA nasal swabs that were initially negative but converted to positive, and the types of MRSA infections. Methods This was a retrospective chart review of AML patients with a suspected infection and a MRSA nasal swab collected at YNHH between 2013 and 2018. Patients were excluded if < 18 years old, prior confirmed MRSA infection or positive MRSA nasal swab within the past year. Results 194 patients were identified with 484 discrete encounters analyzed. Hematopoietic stem cell transplantation occurred in 83 (43%) patients. A total of 468 (97%) encounters had a negative MRSA nasal swab upon admission with no CD MRSA infection during their hospitalization. Three encounters (0.6%) had a negative MRSA nasal swab with a subsequent CD MRSA infection during their admission. Identified infections were bacteremia (2) and pneumonia (1). Median duration from the negative MRSA nasal swab to CD infection was 16 days. Thirteen encounters (3%) had a positive MRSA nasal swab, 5 of which had a CD MRSA infection. Infections included bacteremia (3), pneumonia (2), and sputum with negative chest X-ray (1). MRSA nasal swab had a sensitivity of 57% (CI 0.56–0.58), specificity of 98% (CI 0.98–0.98) positive predictive value of 31% (CI 0.3–0.32), and NPV of 99% (CI 0.99–0.99). Conclusion The results of this retrospective study demonstrate that a negative MRSA nasal swab has a 99% NPV for subsequent MRSA infections in AML patients with no prior history of MRSA colonization or infection. Based on these findings, a negative MRSA nasal swab can help guide de-escalation of empiric MRSA antibiotic therapy in this immunosuppressed population. Disclosures All authors: No reported disclosures.

scholarly journals The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia

2019 ◽  
Vol 8 (11) ◽  
pp. 1985 ◽  
Author(s):  
Christelle Castañón ◽  
Ahinoa Fernández Moreno ◽  
Ana María Fernández Verdugo ◽  
Javier Fernández ◽  
Carmen Martínez Ortega ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Bacterial Infections ◽  
Multidrug Resistant ◽  
Induction Phase ◽  
Gram Negative ◽  
Risk Of Death ◽  
Surveillance Cultures ◽  
Fluoroquinolone Prophylaxis ◽  
Acute Myeloid

Multidrug resistant Gram-Negative Bacterial Infections (MR-GNBI) are an increasing cause of mortality in acute myeloid leukemia (AML), compromising the success of antineoplastic therapy. We prospectively explored a novel strategy, including mandatory fluoroquinolone prophylaxis, weekly surveillance cultures (SC) and targeted antimicrobial therapy for febrile neutropenia, aimed to reduce infectious mortality due to MR-GNBI. Over 146 cycles of chemotherapy, cumulative incidence of colonization was 50%. Half of the colonizations occurred in the consolidation phase of treatment. Application of this strategy led to a significant reduction in the incidence of GNB and carbapenemase-producing Klebisella pneumoniae (cpKp) species, resulting in a reduction of infectious mortality (HR 0.35 [95%, CI 0.13–0.96], p = 0.042). In multivariate analysis, fluroquinolone prophylaxis in addition to SC was associated with improved survival (OR 0.55 [95% CI 0.38–0.79], p = 0.001). Targeted therapy for colonized patients did not overcome the risk of death once cpKp or XDR Pseudomonas aeruginosa infections were developed. Mortality rate after transplant was similar between colonized and not colonized patients. However only 9% of transplanted patients were colonized by cpkp. In conclusion, colonization is a common phenomenon, not limited to the induction phase. This strategy reduces infectious mortality by lowering the global incidence of GN infections and the spread of resistant species.

#15: Risk Factors of Infection related mortality in Pediatric Acute Myeloid Leukemia- Single Institute Experience: 2016–2018

2021 ◽  
Vol 10 (Supplement_2) ◽  
pp. S1-S1
Author(s):  
Ahmed Bayoumi
Keyword(s):  
Risk Factors ◽  
Septic Shock ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Infectious Complications ◽  
P Value ◽  
Gram Negative ◽  
Gram Negative Bacteremia ◽  
Febrile Episodes ◽  
Acute Myeloid

Abstract Children with acute myeloid leukemia (AML) are at a particularly high risk for infectious complications related to the highly intensive chemotherapy. Infections leads to mortality and prolong hospitalization. The aim of the study is to evaluate the risk factors, infectious complications and assess outcome of febrile episodes during induction and consolidation chemotherapy courses in children with AML at the Pediatric Oncology Department, National Cancer Institute, Cairo University from January 2016 to December 2018. Infectious complications were evaluated retrospectively in 621 febrile episodes. Mortality from gram negative bacteremia was 29.9%, in febrile episodes with multidrug resistant gram negative bacteremia: Mortality was 39.2 % in febrile episodes with multidrug resistant gram negative bacteremia and septic shock. Mortality was 71.8 % (p value &lt;0.001). Mortality was high in early chemotherapy phase (intensive timing). Infection related mortality was 39%. In our institute there is epidemiological shift towards gram negative organisms. Sepsis and septic shock are major causes of mortality during chemotherapy-induced neutropenia. Thus, awareness of the presenting characteristics and prompt management is most important. Improved management of sepsis during neutropenia may reduce the mortality of pediatric Acute myeloid leukemia. It is Important to trace the risk factors that may affect the outcome of febrile episodes. Summary of Significant laboratory and clinical predictors of mortality Risk Factor Mortality p value Septic shock 55% &lt;0.001 Septic shock with MDRO 72% Cardiac impairment/inotropic support 65.60% Presence Of Central venous line 18.30% Episode duration &gt;18 days 20.50% Start of antimicrobial in relation to start of chemotherapy &lt; 16 days 33% Episodes: Not in remission 15.60% Risk factor Mortality p value CRP more than or equals 90 mg/l 24.4% Not significant ANC LESS THAN 500 29.9% 0.003 Hgb less than or equals to 7 g/dl 19.9% 0.633 Platelets less than 20000/cc 29.9% 0.299 Liver impairment (grades 3 and 4) 42.2% 0.025 Electrolyte imbalance (grades 3 and 4) 24.1% 0.003 Renal impairment 56.8% 0.025 Coagulopathy 41% &lt;0.001

Second Bacteremia During Antibiotic Treatment In Children With Acute Myeloid Leukemia: A Report From The Canadian Infections In AML Research Group

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1415-1415
Author(s):  
Thai Hoa Tran ◽  
Rochelle Yanofsky ◽  
Donna Johnston ◽  
David Dix ◽  
Biljana Gillmeister ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Antibiotic Treatment ◽  
Myeloid Leukemia ◽  
Conflicts Of Interest ◽  
Gram Positive ◽  
Hematopoietic Stem ◽  
Gram Negative ◽  
Acute Myeloid

Abstract Background The risk of second bacteremia during antibiotic treatment for initial bacteremia is unknown in high-risk populations. Objectives were to describe the prevalence of second bacteremia during treatment and identify risk factors in children with acute myeloid leukemia (AML). Methods We conducted a retrospective, population-based cohort study that included children and adolescents with de novo, non-M3 AML who were diagnosed and treated between January 1, 1995 and December 31, 2004 at 15 Canadian centers. Patients were monitored for bacteremia during chemotherapy until completion of treatment, hematopoietic stem cell transplantation, relapse, refractory disease, or death. Results There were 290 episodes of bacteremia occurring in 185 (54.3%) of 341 children. Eighteen (6.2%) had a second bacteremia while receiving antibiotic treatment. Two episodes of second bacteremia were complicated by sepsis; there were no infection-related deaths. Eleven episodes (61.1%) had either an initial Gram-positive and subsequent Gram-negative bacteremia or initial Gram-negative followed by Gram-positive bacteremia. Days receiving corticosteroids (odds ratio (OR) 1.09, 95% confidence interval (CI) 1.07-1.12; P<0.0001), cumulative dose of corticosteroids (OR 1.04, 95% CI 1.00-1.08; P=0.035) and days of neutropenia from start of course to initial bacteremia (OR 1.07, 95% CI 1.02-1.12; P=0.007) were significantly associated with second bacteremia. Conclusion In pediatric AML, 6% will experience a second bacteremia during antibiotic treatment; duration of corticosteroid exposure and neutropenia are risk factors. These patients remain at high risk for second bacteremia after identification of the initial bacteremia and warrant continued broad-spectrum treatment during profound neutropenia. Abbreviations CONS: coagulase negative Staphylococcus ; VGS: viridans group Streptococcus; Amp: ampicillin; Cz: ceftazidime; Cef: cefotaxime; Cipro: ciprofloxacin; Clin: clindamycin; Clox: cloxacillin; G: gentamicin; Metro: metronidazole; Mero: meropenem; O: oxacillin; Pip: piperacillin; Ta: piperacillin/tazobactam; Tm:ticarcillin/clavulanate; To: tobramycin; V: vancomycin. Disclosures: No relevant conflicts of interest to declare.

Common Polymorphisms of the Interleukin-6 and Chitotriosidase Genes Are Associated with the Risk for Infection with Gram-Negative Bacteria in Children Undergoing Therapy for Acute Myeloid Leukemia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1061-1061
Author(s):  
Thomas Lehrnbecher ◽  
Toralf Bernig ◽  
Mitra Hanisch ◽  
Ulrike Koehl ◽  
Dirk Reinhardt ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Innate Immunity ◽  
Acute Myeloid Leukemia ◽  
Candidate Gene ◽  
Interleukin 6 ◽  
Myeloid Leukemia ◽  
Gram Negative Bacteria ◽  
Necrosis Factor Alpha ◽  
Gram Negative ◽  
Acute Myeloid

Abstract Purpose: Infectious complications remain a substantial cause of morbidity and mortality in patients with acute myeloid leukemia (AML). Candidate gene studies have identified common polymorphisms in genes of molecules of innate immunity as risk factors for susceptibility and/or outcome to a spectrum of pathogens in various populations. This study was performed to investigate whether common polymorphism in genes of innate immunity might influence the risk for serious infection during therapy for pediatric AML. Patients and Methods: Genotype analysis was performed in 168 children treated on clinical trial AML-BFM 93. Infectious events were categorized as microbiologically or clinically documented infections and as fever without an identifiable source. Candidate gene polymorphisms included tumor necrosis factor-alpha, interleukin 6 and 8 (IL6 and IL8), myeloperoxidase, chitotriosidase (CHIT), the low affinity Fc receptor 2A, and the toll like-receptors 2 and 4. Results: The 168 children treated according to clinical trial AML-BFM 93 experienced a total of 508 infectious episodes. Only three patients escaped significant infectious complication. One-hundred-and-ten patients had a least one microbiologically documented infection. Gram-positive bacteria were isolated in the bloodstream of 84 children, whereas Gram-negative bacteria were recovered from the bloodstream of 24 patients. There was an association between Gram-negative bacterial infection and each of the IL6 and CHIT genetic variants. The risk of bacteremia with Gram-negative organisms was significantly higher in patients with the G allele in the IL6 promoter at 174bp [22/123 (17.9%) vs 0/25 (0%); P=.022 (OR 11.31, 95% CI 1.41–90.6)] and in patients with the H allele (24-bp duplication in exon 10) of CHIT [13/56 (23.25) vs 11/112 (9.8%); P=.020 (OR 2.78; 95% CI 1.18–6.54)]. No significant association of the other variant genotypes with any of the clinical endpoints analyzed was observed. Conclusion: The data suggest that variant alleles of both IL6 and CHIT influence susceptibility to infection with Gram-negative bacteria in children undergoing therapy for AML. Further studies are warranted to confirm our findings and to investigate underlying mechanisms.

Sign in / Sign up

Export Citation Format

Share Document